User login
Key clinical point: Repeated active transcranial direct current stimulation (tDCS) for at least 4 weeks significantly reduced migraine pain intensity and resulted in a trend for reduction in the duration of a migraine episode.
Major finding: Patients treated with active vs. sham tDCS showed a significantly higher reduction of pain intensity (mean difference [MD], −1.44; P less than .01) and a trend for reduction in migraine duration (MD, −1.31; P = .14).
Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 104 patients with migraine with/without aura and chronic migraine who received either active or sham tDCS.
Disclosures: No information on funding was available. The authors declared no conflicts of interest.
Source: Cai G et al. J Pain Res. 2021 Apr 27. doi: 10.2147/JPR.S295704.
Key clinical point: Repeated active transcranial direct current stimulation (tDCS) for at least 4 weeks significantly reduced migraine pain intensity and resulted in a trend for reduction in the duration of a migraine episode.
Major finding: Patients treated with active vs. sham tDCS showed a significantly higher reduction of pain intensity (mean difference [MD], −1.44; P less than .01) and a trend for reduction in migraine duration (MD, −1.31; P = .14).
Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 104 patients with migraine with/without aura and chronic migraine who received either active or sham tDCS.
Disclosures: No information on funding was available. The authors declared no conflicts of interest.
Source: Cai G et al. J Pain Res. 2021 Apr 27. doi: 10.2147/JPR.S295704.
Key clinical point: Repeated active transcranial direct current stimulation (tDCS) for at least 4 weeks significantly reduced migraine pain intensity and resulted in a trend for reduction in the duration of a migraine episode.
Major finding: Patients treated with active vs. sham tDCS showed a significantly higher reduction of pain intensity (mean difference [MD], −1.44; P less than .01) and a trend for reduction in migraine duration (MD, −1.31; P = .14).
Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 104 patients with migraine with/without aura and chronic migraine who received either active or sham tDCS.
Disclosures: No information on funding was available. The authors declared no conflicts of interest.
Source: Cai G et al. J Pain Res. 2021 Apr 27. doi: 10.2147/JPR.S295704.